title: Development Considerations for Nanocrystal Drug Products.
abstract: Nanocrystal technology has emerged as a valuable tool for facilitating the delivery of poorly water-soluble active pharmaceutical ingredients (APIs) and enhancing API bioavailability. To date, the US Food and Drug Administration (FDA) has received over 80 applications for drug products containing nanocrystals. These products can be delivered by different routes of administration and are used in a variety of therapeutic areas. To aid in identifying key developmental considerations for these products, a retrospective analysis was performed on the submissions received by the FDA to date. Over 60% of the submissions were for the oral route of administration. Based on the Biopharmaceutics Classification System (BCS), most nanocrystal drugs submitted to the FDA are class II compounds that possess low aqueous solubility and high intestinal permeability. Impact of food on drug bioavailability was reduced for most nanocrystal formulations as compared with their micronized counterparts. For all routes of administration, dose proportionality was observed for some, but not all, nanocrystal products. Particular emphasis in the development of nanocrystal products was placed on the in-process tests and controls at critical manufacturing steps (such as milling process), mitigation and control of process-related impurities, and the stability of APIs or polymorphic form (s) during manufacturing and upon storage. This emphasis resulted in identifying challenges to the development of these products including accurate determination of particle size (distribution) of drug substance and/or nanocrystal colloidal dispersion, identification of polymorphic form (s), and establishment of drug substance/product specifications.
authors.affiliation: Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.
authors.forename: Mei-Ling
authors.initials: ML
authors.lastname: Chen
authors.affiliation: Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.
authors.forename: Mathew
authors.initials: M
authors.lastname: John
authors.affiliation: Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.
authors.forename: Sau L
authors.initials: SL
authors.lastname: Lee
authors.affiliation: Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA. katherine.tyner@fda.hhs.gov.
authors.forename: Katherine M
authors.initials: KM
authors.lastname: Tyner
mesh_terms: D004345:Drug Industry / Q000379:methods / Q000592:standards / Q000706:statistics & numerical data*; D053758:Nanoparticles; D036103:Nanotechnology / Q000706:statistics & numerical data*; D004364:Pharmaceutical Preparations / Q000737:chemistry* / Q000592:standards
chemical_list: D004364:Pharmaceutical Preparations
keywords: absorption; biopharmaceutics; nanocrystal; nanotechnology; quality